Treatment
Fludarabine clinical trials
We’re tracking 299 recruiting studies that include Fludarabine, each written for real people, not researchers, below.
Recruiting studies
- NCT04375631RecruitingPhase 1
Study of chemo plus donor stem cell transplant for blood cancers
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Seattle, WashingtonAges 18 years+ - NCT04510051RecruitingPhase 1
CAR T cell therapy for IL13Rα2 positive pediatric brain tumors
This Phase 1 study tests a type of immune therapy (CAR T cells) for children with brain tumors that come back or do not respond to standard treatment. The cells are given after chemotherapy that temporarily lowers the body’s immune system, which may help the CAR T cells work better.
Duarte, CaliforniaAges 4–25 - NCT04545762RecruitingPhase 1
Anti-CD19 CAR-T for certain relapsed lymphoma
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
San Francisco, CaliforniaAges 18 years+ - NCT04558736RecruitingPhase 2
Haploidentical transplant for severe aplastic anemia in children
This trial tests a “half-matched” stem cell transplant for children and teens with severe aplastic anemia when a fully matched donor isn’t available. It may help rebuild blood-making cells after prior treatments did not work well enough.
Memphis, TennesseeAges Up to 21 years - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT04644016RecruitingPhase 2
Cord blood transplant for children and young adults with blood cancers
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
New York, New YorkAges Up to 21 years - NCT04678401RecruitingPhase 1
Trial tests transplant using a half-matched donor for high-risk leukemia
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Boston, MassachusettsAges 18–75 - NCT04708054RecruitingPhase 2/Phase 3
Venetoclax with busulfan chemo for high-risk AML or MDS
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
Houston, TexasAges 18–70 - NCT04784052RecruitingPhase 1/Phase 2
Briquilimab with reduced donor stem cell transplant for Fanconi anemia
This study tests whether a reduced-intensity donor stem cell transplant (with briquilimab as part of the conditioning) can safely treat bone marrow failure in people with Fanconi anemia. It may help by lowering how much intensive treatment is needed before the transplant, while still helping the donor cells grow.
Stanford, CaliforniaAges 2 years+ - NCT04848064RecruitingPhase 1
Natural killer cells plus mogamulizumab for skin lymphoma
This early-phase study tests a combination of “natural killer” immune cells and a medicine called mogamulizumab to treat certain skin lymphomas that have come back or did not respond. It may help your immune system better find and attack cancer cells.
Columbus, OhioAges 18 years+ - NCT04881240RecruitingPhase 1
Donor-made memory T-cell therapy for hard-to-treat leukemia
This Phase 1 study tests an immune-cell therapy made from a matched donor to treat relapsed or refractory CD19-positive leukemia. It may help patients who have limited options, especially those who cannot receive the standard donor-cell or self-made (autologous) CD19 CAR T-cell therapy.
Memphis, TennesseeAges Up to 21 years - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT04897321RecruitingPhase 1
CAR T therapy for children with B7-H3 solid tumors
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
Memphis, TennesseeAges Up to 21 years - NCT05735717RecruitingPhase 2
T-cell transplant using depleted receptors for blood cancers
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Birmingham, AlabamaAges 18 years+ - NCT04959175RecruitingPhase 1/Phase 2
Lower post-transplant drug doses for older or unfit patients
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
Bethesda, MarylandAges 12–85 - NCT05003895RecruitingPhase 1
CAR-T for solid tumors with high GPC3 protein
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Bethesda, MarylandAges 18–120 - NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT05296564RecruitingPhase 1/Phase 2
TCR cell therapy for NY-ESO-1 positive metastatic cancers
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
JerusalemAges 18–70 - NCT05317403RecruitingPhase 1
Venetoclax plus chemo to change cancer cell behavior
This Phase 1 trial tests whether venetoclax, combined with chemotherapy and a “cancer cell behavior” medicine strategy, can improve treatment for people with AML that has come back or not gone into remission. It’s mainly looking at safety and early signs of benefit.
Milwaukee, WisconsinAges 1–25 - NCT05323201RecruitingPhase 1/Phase 2
B7H3 CAR-T therapy for advanced liver cancer
This trial tests an immune therapy made from your own blood cells (CAR-T) to treat advanced, unresectable liver cancer. It’s designed for people whose tumor has a specific marker called B7H3 and who meet blood, organ, and safety requirements.
Xuzhou, JiangsuAges 18–70 - NCT05327023RecruitingPhase 1/Phase 2
Donor immune cells after bone marrow transplant for high-risk blood cancers
This trial studies giving donor lymphocyte (immune) infusions after a bone marrow transplant for people with high-risk blood cancers. The goal is to help the immune system better fight the cancer and improve outcomes after transplant.
Bethesda, MarylandAges 12–120 - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05436418RecruitingPhase 1/Phase 2
Lower-dose transplant medicines to prevent graft-versus-host disease
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Duarte, CaliforniaAges 12–120
Common questions
- Are there clinical trials studying Fludarabine?
- Yes. Clin2 currently lists 299 recruiting studies that include Fludarabine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Fludarabine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Fludarabine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Fludarabine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.